Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890018 | 1.00 | P4HB (0.44) | P4HBAPPPOLBPKMKDR | |
| SCHEMBL6031435 | 0.82 | APP (0.50) | P4HBAPPPOLBPKM | |
| SCHEMBL6031437 | 0.82 | APP (0.50) | P4HBAPPPOLBPKM | |
| SCHEMBL8154678 | 0.82 | PELI1 (0.44) | PELI1SLC22A12CYP1A2 | |
| SCHEMBL8154684 | 0.82 | PELI1 (0.44) | PELI1SLC22A12CYP1A2 | |
| SCHEMBL17574580 | 0.79 | RXRA (0.41) | P4HBSLC22A12SCN9AARRXRA | |
| SCHEMBL6030726 | 0.78 | APP (0.47) | APPPOLBPKMKDRPELI1 | |
| SCHEMBL3894458 | 0.78 | APP (0.47) | APPPOLBPKMKDRPELI1 | |
| SCHEMBL31173121 | 0.77 | KIF11 (0.47) | SLC22A12AR | |
| SCHEMBL16682648 | 0.77 | KIF11 (0.47) | SLC22A12AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102046-B2 | By reaction of haloaromatics or arylsulfonates with olefins in presence of palladium catalyst, bulky nitrogen base and salt | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | disclosed |
| US-20030105353-A1 | Process for the arylation of olefins | LANXESS DEUTSCHLAND GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105353-A1 | Process for the arylation of olefins | NEK6, JUN, AOC2 | P4HB 1062/4885APP 4380/4885POLB 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.